Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma

Blood (2023) 142 (10): 887–902.

https://doi.org/10.1182/blood.2022019419

Published: 2023

Includes: Supplemental data

Journal Articles

Constitutive PRMT5 Expression Drives Spontaneous Lymphoblastic Lymphoma In Vivo

Lynda Villagomez, Porsha Smith, Fengting Yan, Victor Chen, Shelby Sloan, John T. Patton, Mackenzie Long, Fiona Brown, Elshafa H. Ahmed, Natarajan Muthusamy, Vincenzo Coppola, Anjali Mishra, Kris Vaddi, Peggy Scherle, Rosa Lapalombella, Lapo Alinari, Robert A. Baiocchi

Blood (2022) 140 (Supplement 1): 6381–6382.

https://doi.org/10.1182/blood-2022-168160

Published: 2022

Journal Articles

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

Claire Hinterschied, Fiona Brown, Janani Ravikrishnan, JoBeth Helmig-Mason, Kaylee R. Harrison, Aneeq Yasin, Shelby Sloan, Mackenzie Long, Neha Bhagwat, Kris Vaddi, Peggy Scherle, Jennifer A. Woyach, Selina Chen-Kiang, Olivier Elemento, Jihye Paik, Robert A. Baiocchi

Blood (2022) 140 (Supplement 1): 3118–3119.

https://doi.org/10.1182/blood-2022-167712

Published: 2022

Journal Articles

PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Blood (2022) 140 (Supplement 1): 3116–3117.

https://doi.org/10.1182/blood-2022-167988

Published: 2022

Journal Articles

Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways

Mackenzie Long, Shirsha Koirala, Shelby Sloan, Fiona Brown, Sheetal Tallada, Claire Hinterschied, Kara Corps, JoBeth Helmig-Mason, Ji Hyun Chung, Peggy Scherle, Kris Vaddi, Cem Meydan, Jonathan Foox, Daniel Butler, Christopher E Mason, Lapo Alinari, Bradley W Blaser, Robert A. Baiocchi

Blood (2022) 140 (Supplement 1): 3103–3104.

https://doi.org/10.1182/blood-2022-164641

Published: 2022

Journal Articles

The FOXO1 TAD -p300-Mediated Lineage Survival Transcription Program Is a Targetable Dependency of Mantle Cell Lymphoma

Ja-Young Jang, Heng Pan, Maurizio Di Liberto, Lapo Alinari, Giorgio Inghirami, Robert A. Baiocchi, Olivier Elemento, Selina Chen-Kiang, Jihye Paik

Blood (2022) 140 (Supplement 1): 1692–1693.

https://doi.org/10.1182/blood-2022-165655

Published: 2022

Journal Articles

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD + Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 681–682.

https://doi.org/10.1182/blood-2022-165573

Published: 2022

Journal Articles

Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies - Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113

Stefan K. Barta, Ariela Noy, Marcelo C Pasquini, Naya He, Tiffany Hunt, Carlos Litovich, Uroosa Ibrahim, Robert A. Baiocchi, Richard F. Ambinder

Blood (2022) 140 (Supplement 1): 1847–1848.

https://doi.org/10.1182/blood-2022-165370

Published: 2022

Journal Articles

Methylome Analysis of Epstein-Barr Virus with Nanopore Sequencing Reveals Viral State Dynamics

Christoph Weigel, Esko Kautto, Elshafa H. Ahmed, Yue-Zhong Wu, Charles T. Gregory, Ada C. Cleary, Sarah Y. Schlotter, Eric Brooks, Mark Lustberg, Robert A. Baiocchi, James S. Blachly, Christopher C. Oakes

Blood (2022) 140 (Supplement 1): 8772–8773.

https://doi.org/10.1182/blood-2022-159739

Published: 2022

Journal Articles

Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers

Narendranath Epperla, Xinyu Wang, Hong Li, David A. Bond, Yazeed Sawalha, John C. Reneau, Timothy J. Voorhees, Kami J. Maddocks, Beth Christian, Walter Hanel, Lapo Alinari, Lalit Sehgal, Robert A. Baiocchi, James L. Lee

Blood (2022) 140 (Supplement 1): 11873–11875.

https://doi.org/10.1182/blood-2022-164907

Published: 2022

Journal Articles

PRMT5 Inhibition Reduces Autoinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis

Polina Shindiapina, Rachel Saadey, Aneeq Yasin, Charlene Mao, Alexa Wandke, Elshafa Hassan Ahmed, Ethan Baiocchi, Kris Vaddi, Peggy Scherle, Fiona Brown, Anna Mozhenkova, Ikbale El Ayachi, Austin D. Schenk, Shelby Sloan, Kaylee Harrison, JoBeth Helmig-Mason, Robert A. Baiocchi

Blood (2022) 140 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2022-170239

Published: 2022

Journal Articles

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV + PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Wei Ye, Susan Prockop

Blood (2022) 140 (Supplement 1): 10374–10376.

https://doi.org/10.1182/blood-2022-157766

Published: 2022

Journal Articles

Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 8746–8747.

https://doi.org/10.1182/blood-2022-169949

Published: 2022

Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1588.

https://doi.org/10.1182/blood-2019-129687

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Ashley E. Rosko, MD, Sarah A Wall, MD, Robert A Baiocchi, MD PhD, Don M. Benson, Jr., MD PhD, Jonathan E. Brammer, MD, John C. Byrd, MD, Yvonne A. Efebera, MD MPH, Kami J. Maddocks, MD, Kerry A. Rogers, MD, Carolyn Presley, MD, Desiree Jones, Ying Huang, MS, MA, Michelle Naughton, PhD MPH

Blood (2019) 134 (Supplement_1): 4776.

https://doi.org/10.1182/blood-2019-130531

Published: 2019

Journal Articles

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Fiona Brown, BS, Yang Zhang, PhD, Claire Hinterschied, Alexander Prouty, BS, Shelby Sloan, BS, JoBeth Helmig-Mason, Msc, Ji Hyun Chung, PhD, Kris Vaddi, PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Lapo Alinari, MD PhD, Peggy Scherle, PhD, Rosa Lapalombella, PhD, Jihye Paik, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 302.

https://doi.org/10.1182/blood-2019-130797

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

Targeting Hypersumoylation in Mantle Cell Lymphoma

Walter Hanel, MD PhD, Liudmyla Tsyba, PhD, Dennis Huszar, PhD, Alex Prouty, Xiaoli Zhang, PhD, JoBeth Helmig-Mason, Msc, Bethany L Mundy-Bosse, PhD, Youssef Youssef, MD, Samir Parekh, MD, Kami J. Maddocks, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4060.

https://doi.org/10.1182/blood-2019-127363

Published: 2019

Journal Articles

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Shelby Sloan, BS, Fiona Brown, BS, JI Hyun Chung, PhD, Alexander Prouty, BS, Esther Wheeler, BS, Bonnie K Harrington, DVM, PhD, Eric Brooks, BS, Ayse S Yilmaz, MS, Hatice G Ozer, PhD, John C. Byrd, MD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Rosa Lapalombella, PhD, Kris Vaddi, PhD, Peggy Scherle, PhD, Youssef Youssef, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4065.

https://doi.org/10.1182/blood-2019-128998

Published: 2019

NARROW

PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma

Constitutive PRMT5 Expression Drives Spontaneous Lymphoblastic Lymphoma In Vivo

PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways

The FOXO1 TAD -p300-Mediated Lineage Survival Transcription Program Is a Targetable Dependency of Mantle Cell Lymphoma

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD + Acute Myeloid Leukemia

Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies - Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113

Methylome Analysis of Epstein-Barr Virus with Nanopore Sequencing Reveals Viral State Dynamics

Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers

PRMT5 Inhibition Reduces Autoinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis

Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Targeting Hypersumoylation in Mantle Cell Lymphoma

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only